Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

Bristol Myers Squibb (BMS) and BioNTech have partnered to co-develop and co-commercialize the bispecific antibody drug BNT327, targeting multiple solid tumor types14.

BMS is committing over $11 billion to the collaboration, which includes $1.5 billion upfront, $2 billion in near-term payments through 2028, and up to $7.6 billion in additional milestone payments45.

BNT327 is a bispecific antibody that targets PD-L1 and VEGF-A, two proteins involved in tumor immune evasion and blood vessel formation, respectively234.

Both companies will split the global profits, losses, and development/manufacturing costs 50-504.

This partnership positions BMS to be competitive in the rapidly expanding bispecific antibody market for cancer treatment5.

Sources:

1. https://www.contractpharma.com/breaking-news/biontech-bms-partner-to-develop-commercialize-bnt327-for-solid-tumors/

2. https://medcitynews.com/2025/06/biontech-bristol-myers-squibb-partnership-bispecific-antibody-cancer-pd-l1-vegf-bmy-bntx/

3. https://www.biopharmadive.com/news/biontech-bristol-myers-pd1-vegf-bispecific-cancer-partnership/749505/

4. https://www.statnews.com/2025/06/02/bristol-myers-squibb-biontech-vegf-pdl1-bispecific-antibody-cancer/

5. https://lifesciencewa.org/2025/06/03/bristol-myers-squibb-commits-up-to-11b-to-work-with-biontech-on-solid-tumor-bispecific/